The nation of Zimbabwe has rejected a significant American health deal worth 367 million US dollars (272 million pounds) spanning five years due to the United States' request for sensitive biological samples.
This rejection became public after a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official representative later stated that the US was demanding access to biological samples for research and commercial purposes while refused to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued negotiations to secure a deal agreeable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Implications
This rejection comes after a similar case in Kenya, where a court blocked a related deal with the US following legal challenges were raised about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to boost transparency and accountability.
Based on statements, Sixteen African countries have so far signed similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our country would supply the basic resources for medical research with no assurance that the final treatments would be available to our people should a new health crisis arise."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting systems already established through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This system is designed to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome continued discussions with our US partners on how future co-operation might be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body said it recognised the official position, but suggested that talks must proceed since much of the nation's Aids initiatives were funded by foreign aid.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
This impasse highlights the continuing tensions between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.